FANAPT (iloperidone) by Vanda Pharmaceuticals is unknown. First approved in 2009.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
FANAPT (iloperidone) is an atypical antipsychotic oral tablet approved in 2009 for schizophrenia treatment. The drug works through dopamine D2 and serotonin 5-HT2 antagonism, with an active metabolite (P88) that mirrors the parent compound's receptor profile. Iloperidone is positioned as a second-generation antipsychotic option in a mature therapeutic class.
Drug is at peak commercial stage with stable $93M annual spending; team focused on maintaining market share in competitive atypical antipsychotic segment.
unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.
Atypical Antipsychotic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Worked on FANAPT at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on FANAPT offers exposure to mature market dynamics, competitive positioning, and lifecycle management in a crowded therapeutic class. Career growth is constrained by LOE approaching in 5.5 years; roles focus on maximizing current market share before generic erosion.